Hepion Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HEPA research report →
Companywww.hepionpharma.com
Hepion Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms.
- CEO
- Gary S. Stetz
- IPO
- 2014
- Employees
- 22
- HQ
- Edison, NJ, US
Price Chart
Valuation
- Market Cap
- $1.02M
- P/E
- -0.34
- P/S
- 0.00
- P/B
- 0.55
- EV/EBITDA
- 0.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -102.45%
- ROIC
- -186.89%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-8,277,850 · 37.25%
- EPS
- $-0.88 · 99.18%
- Op Income
- $-4,163,691
- FCF YoY
- 82.04%
Performance & Tape
- 52W High
- $0.25
- 52W Low
- $0.03
- 50D MA
- $0.06
- 200D MA
- $0.06
- Beta
- 1.65
- Avg Volume
- 23.52K
Get TickerSpark's AI analysis on HEPA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 21, 26 | Purcell Michael J. | buy | 1,250,000 |
| Apr 21, 26 | LoPriore Vincent S | buy | 1,250,000 |
| Apr 21, 26 | LoPriore Vincent S | buy | 5,000,000 |
| Apr 21, 26 | Appajosyula Sireesh | buy | 1,250,000 |
| Apr 21, 26 | Stetz Gary S. | buy | 1,250,000 |
| Mar 16, 26 | Stetz Gary S. | other | 0 |
| Mar 16, 26 | LoPriore Vincent S | other | 0 |
| Mar 16, 26 | Appajosyula Sireesh | other | 0 |
| Mar 6, 24 | Purcell Michael J. | other | 50,000 |
| Mar 5, 24 | Purcell Michael J. | other | 0 |
Our HEPA Coverage
We haven't published any research on HEPA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HEPA Report →